Moreover, at CNA level, we found high ITH of druggable gene EGFR and FGFR1 in approximately 50% FGFR1- and EGFR-amplified cases, indicating that the mutation status of these two targets from single-tumor sequencing may underestimate their ITH. This evidence concerns the gene FGFR1 and neoplasm.